Ventyx Biosciences Inc
NASDAQ:VTYX
Ventyx Biosciences Inc
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in Encinitas, California and currently employs 27 full-time employees. The company went IPO on 2021-10-21. The firm is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. The company is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The firm is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in Encinitas, California and currently employs 27 full-time employees. The company went IPO on 2021-10-21. The firm is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. The company is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The firm is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.
Pipeline Progress: Ventyx highlighted strong progress across its NLRP3 inhibitor portfolio, with new positive Phase I and II results and multiple Phase II trials planned for 2024.
Financial Position: The company ended Q1 with $302.6 million in cash, cash equivalents, and marketable securities, and expects to be funded into at least the second half of 2026.
Expense Trends: Operating expenses and cash outflows are expected to decrease from Q2 2024 onward as several trial wind-downs conclude.
VTX3232 Update: Phase II trials in Parkinson's disease and obesity are planned for the second half of 2024, following positive Phase I data showing strong target coverage and safety.
VTX2735 Advances: Positive Phase II results in CAPS were reported; development is moving toward cardiovascular indications including recurrent pericarditis and MACE prevention.
VTX002 (Ulcerative Colitis): The program is Phase III-ready, with ongoing preparations and active partnering discussions after a positive End of Phase 2 meeting with FDA.
VTX958 (Crohn's): Enrollment in the Phase II Crohn's disease trial is complete, and top-line results are expected in early second half of 2024.
